InvestorsHub Logo
Followers 42
Posts 12453
Boards Moderated 0
Alias Born 11/18/2016

Re: cab033 post# 53225

Thursday, 02/08/2018 2:33:45 PM

Thursday, February 08, 2018 2:33:45 PM

Post# of 108192
You omitted some facts. Namely that the CEO and IR have specifically stated that the company is in negotiations for a licensing deal for the EU market. Also, the fact that every young biotech maintains a large cushion of authorized shares. So the assumption that management has a specific use in mind for those shares is nothing more than a guess. Finally, that the vast majority of retention bonuses are to keep people from leaving due to the possibility of a merger or buyout. What conjecture is there in these facts?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News